ArticleGenome medicine2021
Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine.
Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).The oncologist · 2023Trial
- MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6, and EGFR.The journal of pathology. Clinical research · 2026Article
- MYC amplification is common in cancer of the stomach and gastroesophageal junction, correlates with male sex and reduced response to neoadjuvant therapy.BMC cancer · 2026Article
- JAK2 and NOTCH2 in gastric cancer - NOTCH2 is an independent prognosticator of poor patient outcome.Virchows Archiv : an international journal of pathology · 2026Article
- Habitat radiomics assists radiologists in accurately diagnosing lymph node metastasis of adenocarcinoma of the esophagogastric junction.Insights into imaging · 2025Article
- Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution.Cancer discovery · 2025Article
- Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer.Journal of gastric cancer · 2025Article
- A novel computational model ITHCS for enhanced prognostic risk stratification in ESCC by correcting for intratumor heterogeneity.Briefings in bioinformatics · 2024Article
- Identification of collagen subtypes of gastric cancer for distinguishing patient prognosis and therapeutic response.Cancer innovation · 2024Article
- Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma.Pathology international · 2024Review
- Distribution and Clinicopathological Features of Mott Cells (Plasma Cells Containing Russell Bodies) in Gastric Cancer: Presence of Mott Cells Is Associated with Favorable Prognosis.Journal of clinical medicine · 2024Article
- The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.Cancer biomarkers : section A of Disease markers · 2024Article
- Review
- Advancing evolutionary medicine in Northern Germany: Collaboration between Kiel University's Medical Faculty and the Max Planck Institute for Evolutionary Biology.Evolution, medicine, and public health · 2024Article
- Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.Cancer communications (London, England) · 2023Article
- MDM2 amplification is rare in gastric cancer.Virchows Archiv : an international journal of pathology · 2023Article
- Genomic and evolutionary characteristics of metastatic gastric cancer by routes.British journal of cancer · 2023Article
- Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell receptor sequencing.Molecular oncology · 2023Article
- Polymorphism rs1057147 located in mesothelin gene predicts lymph node metastasis in patients with gastric cancer.Applied microbiology and biotechnology · 2023Article
- SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co-amplification.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is a somatic evolutionary disease and adenocarcinomas of the stomach and gastroesophageal junction (GC) may serve as a two-dimensional model of cancer expansion, in which tumor subclones are not evenly mixed during tumor progression but rather spatially separated and diversified. We hypothesize that precision medicine efforts are compromised when clinical decisions are based on a single-sample analysis, which ignores the mechanisms of cancer evolution and resulting intratumoral heterogeneity. Using multiregional whole-exome sequencing, we investigated the effect of somatic evolution on intratumoral heterogeneity aiming to shed light on the evolutionary biology of GC.
methodsThe study comprised a prospective discovery cohort of 9 and a validation cohort of 463 GCs. Multiregional whole-exome sequencing was performed using samples form 45 primary tumors and 3 lymph node metastases (range 3-10 tumor samples/patient) of the discovery cohort.
resultsIn total, the discovery cohort harbored 16,537 non-synonymous mutations. Intratumoral heterogeneity of somatic mutations and copy number variants were present in all tumors of the discovery cohort. Of the non-synonymous mutations, 53-91% were not present in each patient's sample; 399 genes harbored 2-4 different non-synonymous mutations in the same patient; 175 genes showed copy number variations, the majority being heterogeneous, including CD274 (PD-L1). Multi-sample tree-based analyses provided evidence for branched evolution being most complex in a microsatellite instable GC. The analysis of the mode of evolution showed a high degree of heterogeneity in deviation from neutrality within each tumor. We found evidence of parallel evolution and evolutionary trajectories: different mutations of SMAD4 aligned with different subclones and were found only in TP53 mutant GCs.
conclusionsNeutral and non-neutral somatic evolution shape the mutational landscape in GC along its lateral expansions. It leads to complex spatial intratumoral heterogeneity, where lymph node metastases may stem from different areas of the primary tumor, synchronously. Our findings may have profound effects on future patient management. They illustrate the risk of mis-interpreting tumor genetics based on single-sample analysis and open new avenues for an evolutionary classification of GC, i.e., the discovery of distinct evolutionary trajectories which can be utilized for precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.